Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAHLVE Study
2023-506317-22-00Phase 2Completed
- Sponsor
- Region Västra Götaland
- Start
- Sep 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in exudative macular degeneration comparing Bevacizumab arm with Aflibercept arm (2 arms). Primary endpoint: Number of intravitreal injections after two years. Started Sep 2019; status: completed.
02
Drugs
bevacizumabaflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2023-506317-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506317-22-00.